-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is original by Translational Medicine Network.
Please indicate the source for reprinting.
Author: Liz Zee Guide: Cholangiocarcinoma is a primary liver cancer with insidious onset and indistinct early symptoms.
It is usually found late, and it is easy to miss the best treatment period.
The prognosis is poor
.
Even if detected early, the 5-year survival rate after diagnosis is less than 13%
.
Researchers are currently using a new algorithm-DRUML to find potential new treatments for cholangiocarcinoma.
In the future, this algorithm will also be used to prescribe the most effective treatment plan for different patients.
The application of artificial intelligence in biomedicine is expected to be complete Change the diagnosis and treatment of cancer in the future
.
Researchers at King's College Hospital in London and Queen Mary University of London have demonstrated that a new computer-based algorithm can reduce the growth of cancer cells based on drugs used to treat primary liver cancer.
The efficacy of the aspect ranks the drugs
.
The algorithm was named Drug Ranking Using Machine Learning (DRUML) and was previously designed to determine effective treatments for cancer patients
.
The algorithm is based on the analysis of modified proteins commonly found in malignant cells, which are considered to be the key to cell proliferation
.
This is the first time that DRUML has been used to diagnose cholangiocarcinoma (a type of primary liver cancer) as a potential new treatment
.
Researchers say that DRUML may rank other cancer drugs
.
Researchers hope that one day doctors can use this new technology to predict the patient's response to treatment and prescribe the most effective targeted treatment plan
.
This research was funded by the King’s College Hospital Charity Fund and Queen Mary Innovation Co.
, Ltd.
, and was recently published in the American Association of Cancer Research's journal Cancer Research.
The article is titled "Computational analysis of cholangiocarcinoma phosphoproteomes identifies patient -specific drug targets"
.
6200 people in the UK suffer from liver cancer each year
.
This disease is often difficult to detect because patients with early liver cancer will not have symptoms
.
Even if detected early, the 5-year survival rate after diagnosis is less than 13%
.
Cholangiocarcinoma, also known as cholangiocarcinoma (CCA), is a primary liver cancer caused by bile duct cells in the liver
.
The new algorithm was developed after analyzing the bile duct cells and tumors donated by CCA patients (including donors from the Liver Biobank of King's College Hospital) around the world
.
Researchers debugged DRUML at the Butts Cancer Institute, Queen Mary University of London.
By examining data on abnormally expressed (overactive or underactive) proteins, they identified and sequenced the response of a series of cancer cell lines to more than 400 drugs
.
Then DRUML is applied to the donated bile duct cells and tumors in order to make treatment recommendations based on the patient's protein pattern in these cells
.
Professor Pedro Cutillas, a researcher at Queen Mary University of London, said: "Patients diagnosed with primary liver cancer often have a poor prognosis.
.
Especially for cholangiocarcinoma, there are great differences in protein expression and symptoms between different patients
.
This difference causes patients to respond differently to treatment
.
This is why a one-size-fits-all treatment is not the most effective way to reduce the growth of cancer cells, and why we apply DRUML to this type of cancer
.
Dr.
Shirin E Khorsandi, a clinical researcher and principal researcher at King’s College Hospital, said: “The smooth development of our work depends on the generous donations of patients and their families.
They agreed to donate tumor tissues to the liver biobank of King’s College Hospital.
Research to raise funds
.
"We believe that this research represents a major advancement in the field of artificial intelligence, and the participation of more patients will help our new algorithm to select the best drugs for the treatment of multiple mutations in liver cancer
.
"Although this algorithm is still in its infancy, we are optimistic that applying artificial intelligence to one of the most difficult to treat cancers can change the way clinicians diagnose and treat liver cancer in the future
.
"References: https: //cancerres.
aacrjournals.
org/content/early/2021/09/21/0008-5472.
CAN-21-0955 Note: This article is intended to introduce the progress of medical research, treatment programs can not be used as a reference
.
As If you need health guidance, please go to a regular hospital for treatment
.
Popular·Article Diagnostic Test [The Lancet] Call for action! Nearly half of the world's people cannot get basic diagnosis for many common diseases.
Can the COVID-19 pandemic help change the diagnosis? Immunotherapy [Nature Sub-Journal] Lung epithelial cells control lung immunity? This will lay the foundation for the treatment of many lung diseases! Tumor Research 【Research】Be alert! Summarizing 30 years of big data: esophageal adenocarcinoma is showing a younger trend.
Medical trends [News] The Nobel Prize in Physiology or Medicine in 2021 was announced, and the pain receptors won! Intestinal health [PNAS] research has discovered the "second brain" that exists in the intestine, and its glial will open up new ways to treat intestinal diseases! Tumor Research [Nature Sub-Journal] The use of single-cell multi-omics to study tumor cells is a new idea, the Harvard Medical School and other top-level teams have created a precedent! Tumor research [Science] protein may become a new breakthrough in cancer treatment! New Coronavirus [Science] The truth about the source of SARS-CoV-2? The coronavirus that is the closest to the new coronavirus so far has been found in Lao bats, with a matching rate of 96.
8%! Coronavirus [The BMJ] In Israel, where the vaccination rate is 78%, why is the epidemic still out of control? Is there a need to worry about the effectiveness of the new crown vaccine? Is it necessary to strengthen the injection? Organoid Research [Nature Sub-Journal] A 3D pancreatic cancer tumor model cultivated by an international team of scientists including Shanghai Jiaotong University can effectively improve the treatment of pancreatic cancer.
Tumor Research [Science Sub-Journal] Salt has the effect of inhibiting tumors ? Scientists explain unexpected discoveries for you through mouse experiments! Recommendation·Activity The 5th Symposium on Modern Clinical Molecular Diagnosis at the 3rd Shanghai International Cancer Conference
Please indicate the source for reprinting.
Author: Liz Zee Guide: Cholangiocarcinoma is a primary liver cancer with insidious onset and indistinct early symptoms.
It is usually found late, and it is easy to miss the best treatment period.
The prognosis is poor
.
Even if detected early, the 5-year survival rate after diagnosis is less than 13%
.
Researchers are currently using a new algorithm-DRUML to find potential new treatments for cholangiocarcinoma.
In the future, this algorithm will also be used to prescribe the most effective treatment plan for different patients.
The application of artificial intelligence in biomedicine is expected to be complete Change the diagnosis and treatment of cancer in the future
.
Researchers at King's College Hospital in London and Queen Mary University of London have demonstrated that a new computer-based algorithm can reduce the growth of cancer cells based on drugs used to treat primary liver cancer.
The efficacy of the aspect ranks the drugs
.
The algorithm was named Drug Ranking Using Machine Learning (DRUML) and was previously designed to determine effective treatments for cancer patients
.
The algorithm is based on the analysis of modified proteins commonly found in malignant cells, which are considered to be the key to cell proliferation
.
This is the first time that DRUML has been used to diagnose cholangiocarcinoma (a type of primary liver cancer) as a potential new treatment
.
Researchers say that DRUML may rank other cancer drugs
.
Researchers hope that one day doctors can use this new technology to predict the patient's response to treatment and prescribe the most effective targeted treatment plan
.
This research was funded by the King’s College Hospital Charity Fund and Queen Mary Innovation Co.
, Ltd.
, and was recently published in the American Association of Cancer Research's journal Cancer Research.
The article is titled "Computational analysis of cholangiocarcinoma phosphoproteomes identifies patient -specific drug targets"
.
6200 people in the UK suffer from liver cancer each year
.
This disease is often difficult to detect because patients with early liver cancer will not have symptoms
.
Even if detected early, the 5-year survival rate after diagnosis is less than 13%
.
Cholangiocarcinoma, also known as cholangiocarcinoma (CCA), is a primary liver cancer caused by bile duct cells in the liver
.
The new algorithm was developed after analyzing the bile duct cells and tumors donated by CCA patients (including donors from the Liver Biobank of King's College Hospital) around the world
.
Researchers debugged DRUML at the Butts Cancer Institute, Queen Mary University of London.
By examining data on abnormally expressed (overactive or underactive) proteins, they identified and sequenced the response of a series of cancer cell lines to more than 400 drugs
.
Then DRUML is applied to the donated bile duct cells and tumors in order to make treatment recommendations based on the patient's protein pattern in these cells
.
Professor Pedro Cutillas, a researcher at Queen Mary University of London, said: "Patients diagnosed with primary liver cancer often have a poor prognosis.
.
Especially for cholangiocarcinoma, there are great differences in protein expression and symptoms between different patients
.
This difference causes patients to respond differently to treatment
.
This is why a one-size-fits-all treatment is not the most effective way to reduce the growth of cancer cells, and why we apply DRUML to this type of cancer
.
Dr.
Shirin E Khorsandi, a clinical researcher and principal researcher at King’s College Hospital, said: “The smooth development of our work depends on the generous donations of patients and their families.
They agreed to donate tumor tissues to the liver biobank of King’s College Hospital.
Research to raise funds
.
"We believe that this research represents a major advancement in the field of artificial intelligence, and the participation of more patients will help our new algorithm to select the best drugs for the treatment of multiple mutations in liver cancer
.
"Although this algorithm is still in its infancy, we are optimistic that applying artificial intelligence to one of the most difficult to treat cancers can change the way clinicians diagnose and treat liver cancer in the future
.
"References: https: //cancerres.
aacrjournals.
org/content/early/2021/09/21/0008-5472.
CAN-21-0955 Note: This article is intended to introduce the progress of medical research, treatment programs can not be used as a reference
.
As If you need health guidance, please go to a regular hospital for treatment
.
Popular·Article Diagnostic Test [The Lancet] Call for action! Nearly half of the world's people cannot get basic diagnosis for many common diseases.
Can the COVID-19 pandemic help change the diagnosis? Immunotherapy [Nature Sub-Journal] Lung epithelial cells control lung immunity? This will lay the foundation for the treatment of many lung diseases! Tumor Research 【Research】Be alert! Summarizing 30 years of big data: esophageal adenocarcinoma is showing a younger trend.
Medical trends [News] The Nobel Prize in Physiology or Medicine in 2021 was announced, and the pain receptors won! Intestinal health [PNAS] research has discovered the "second brain" that exists in the intestine, and its glial will open up new ways to treat intestinal diseases! Tumor Research [Nature Sub-Journal] The use of single-cell multi-omics to study tumor cells is a new idea, the Harvard Medical School and other top-level teams have created a precedent! Tumor research [Science] protein may become a new breakthrough in cancer treatment! New Coronavirus [Science] The truth about the source of SARS-CoV-2? The coronavirus that is the closest to the new coronavirus so far has been found in Lao bats, with a matching rate of 96.
8%! Coronavirus [The BMJ] In Israel, where the vaccination rate is 78%, why is the epidemic still out of control? Is there a need to worry about the effectiveness of the new crown vaccine? Is it necessary to strengthen the injection? Organoid Research [Nature Sub-Journal] A 3D pancreatic cancer tumor model cultivated by an international team of scientists including Shanghai Jiaotong University can effectively improve the treatment of pancreatic cancer.
Tumor Research [Science Sub-Journal] Salt has the effect of inhibiting tumors ? Scientists explain unexpected discoveries for you through mouse experiments! Recommendation·Activity The 5th Symposium on Modern Clinical Molecular Diagnosis at the 3rd Shanghai International Cancer Conference
